International Association for the Study of Lung Cancer(IASLC) shared a post on LinkedIn:
“2026 TTLC Symposia Event
RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC
Join this engaging CME symposium exploring the evolving treatment landscape of KRAS-mutated NSCLC. This expert-led session will examine the rationale for RAS(ON) inhibition, review emerging clinical trial data, and discuss the potential role of these inhibitors in shaping patient care.
Featuring insights from Dr. Alex Spira and Dr. Kathryn C. Arbour, the program will conclude with a live QandA to address key clinical questions.”
Other articles about IASLC.